TEST:

BT-Reveal™ Early Pancreatic Cancer Test

However, contrast-enhanced MRI demonstrated complete tumor disappearance and normalization of serum tumor marker levels. These findings suggest that post-irradiation 18F-FAPI-74 uptake is more likely attributable to reactive changes, such as radiation-induced hepatic fibrosis, rather than residual or recurrent tumor.

"Breakthrough Genomics...announced today its collaboration with the PRECEDE Consortium to advance the clinical evaluation and adoption of its BT-Reveal™ Early Pancreatic Cancer Test...The partnership with PRECEDE offers Breakthrough Genomics access to a network of the world's foremost pancreatic cancer researchers, clinicians, and high-risk centers. Led by world-renown surgeon and scientist, Dr. Diane Simeone, the PRECEDE Consortium is conducting the largest longitudinal study of its kind, with over 7,000 patients enrolled across 54 leading institutions."